Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.
As Mapp's products transition to clinical evaluation, licenses are transferred to Mapp's commercialization partner, LeafBio.
February 6, 2015 at 8:30 AM - LeafBio, Inc. submitted an Investigational New Drug (IND) application for clinical evaluation of ZMapp™ to the Food and Drug Administration (FDA) on February 3, 2015.
February 27, 2015 at 8:30 AM - Mapp Bio Clinical Trials Press Release
Mapp Biopharmaceutical, Inc.
6160 Lusk Blvd. # C105
San Diego, CA 92121
phone: 858 625 0335
fax: 800 372 2176
|©2012 Mapp Biopharmaceutical, Inc. All rights reserved.|